Multivalent TB vaccines targeting the esx gene family generate potent and broad cell-mediated immune responses superior to BCG

References

• Zumla A, Raviglione M, Hafner R, von Reyn CF. Tuberculosis. N Engl J Med 2013; 368:745 - 55; http://dx.doi.org/10.1056/NEJMra1200894; PMID: 23425167
   PubMed Web of Science ®Google Scholar
• Wright A, Zignol M, Van Deun A, Falzon D, Gerdes SR, Feldman K, Hoffner S, Drobniewski F, Barrera L, van Soolingen D, et al, Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet 2009; 373:1861 - 73; http://dx.doi.org/10.1016/S0140-6736(09)60331-7; PMID: 19375159
   PubMed Web of Science ®Google Scholar
• Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, Fineberg HV, Mosteller F. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 1994; 271:698 - 702; http://dx.doi.org/10.1001/jama.1994.03510330076038; PMID: 8309034
   PubMed Web of Science ®Google Scholar
• Brewer TF. Preventing tuberculosis with bacillus Calmette-Guérin vaccine: a meta-analysis of the literature. Clin Infect Dis 2000; 31:Suppl 3 S64 - 7; http://dx.doi.org/10.1086/314072; PMID: 11010824
   PubMed Web of Science ®Google Scholar
• WHO. Use of BCG vaccine in HIV-infected infants. Wkly Epidemiol Rec 2010; 5:29 - 36
   Google Scholar
• Pitt JM, Blankley S, McShane H, O’Garra A. Vaccination against tuberculosis: how can we better BCG?. Microb Pathog 2013; 58:2 - 16; http://dx.doi.org/10.1016/j.micpath.2012.12.002; PMID: 23257069
   PubMed Web of Science ®Google Scholar
• Tameris MD, Hatherill M, Landry BS, Scriba TJ, Snowden MA, Lockhart S, Shea JE, McClain JB, Hussey GD, Hanekom WA, et al, MVA85A 020 Trial Study Team. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 2013; 381:1021 - 8; http://dx.doi.org/10.1016/S0140-6736(13)60177-4; PMID: 23391465
   PubMed Web of Science ®Google Scholar
• Olsen AW, Williams A, Okkels LM, Hatch G, Andersen P. Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea pig model. Infect Immun 2004; 72:6148 - 50; http://dx.doi.org/10.1128/IAI.72.10.6148-6150.2004; PMID: 15385521
   PubMed Web of Science ®Google Scholar
• Aagaard C, Hoang T, Dietrich J, Cardona PJ, Izzo A, Dolganov G, Schoolnik GK, Cassidy JP, Billeskov R, Andersen P. A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nat Med 2011; 17:189 - 94; http://dx.doi.org/10.1038/nm.2285; PMID: 21258338
   PubMed Web of Science ®Google Scholar
• Skjøt RL, Oettinger T, Rosenkrands I, Ravn P, Brock I, Jacobsen S, Andersen P. Comparative evaluation of low-molecular-mass proteins from Mtb identifies members of the ESAT-6 family as immunodominant T-cell antigens. Infect Immun 2000; 68:214 - 20; http://dx.doi.org/10.1128/IAI.68.1.214-220.2000; PMID: 10603390
   PubMed Web of Science ®Google Scholar
• Louise R, Skjøt V, Agger EM, Andersen P. Antigen discovery and tuberculosis vaccine development in the post-genomic era. Scand J Infect Dis 2001; 33:643 - 7; http://dx.doi.org/10.1080/00365540110026971; PMID: 11669220
   PubMed Web of Science ®Google Scholar
• Brodin P, Rosenkrands I, Andersen P, Cole ST, Brosch R. ESAT-6 proteins: protective antigens and virulence factors?. Trends Microbiol 2004; 12:500 - 8; http://dx.doi.org/10.1016/j.tim.2004.09.007; PMID: 15488391
   PubMed Web of Science ®Google Scholar
• Jones GJ, Gordon SV, Hewinson RG, Vordermeier HM. Screening of predicted secreted antigens from Mycobacterium bovis reveals the immunodominance of the ESAT-6 protein family. Infect Immun 2010; 78:1326 - 32; http://dx.doi.org/10.1128/IAI.01246-09; PMID: 20086089
   PubMed Web of Science ®Google Scholar
• Kamath AT, Feng CG, Macdonald M, Briscoe H, Britton WJ. Differential protective efficacy of DNA vaccines expressing secreted proteins of Mycobacterium tuberculosis. Infect Immun 1999; 67:1702 - 7; PMID: 10085007
   PubMed Web of Science ®Google Scholar
• Mustafa AS, Skeiky YA, Al-Attiyah R, Alderson MR, Hewinson RG, Vordermeier HM. Immunogenicity of Mycobacterium tuberculosis antigens in Mycobacterium bovis BCG-vaccinated and M. bovis-infected cattle. Infect Immun 2006; 74:4566 - 72; http://dx.doi.org/10.1128/IAI.01660-05; PMID: 16861643
   PubMed Web of Science ®Google Scholar
• Morris S, Kelley C, Howard A, Li Z, Collins F. The immunogenicity of single and combination DNA vaccines against tuberculosis. Vaccine 2000; 18:2155 - 63; http://dx.doi.org/10.1016/S0264-410X(99)00540-X; PMID: 10715531
   PubMed Web of Science ®Google Scholar
• Khera A, Singh R, Shakila H, Rao V, Dhar N, Narayanan PR, Parmasivan CN, Ramanathan VD, Tyagi AK. Elicitation of efficient, protective immune responses by using DNA vaccines against tuberculosis. Vaccine 2005; 23:5655 - 65; http://dx.doi.org/10.1016/j.vaccine.2005.03.056; PMID: 16157425
   PubMed Web of Science ®Google Scholar
• Brandt L, Elhay M, Rosenkrands I, Lindblad EB, Andersen P. ESAT-6 subunit vaccination against Mycobacterium tuberculosis. Infect Immun 2000; 68:791 - 5; http://dx.doi.org/10.1128/IAI.68.2.791-795.2000; PMID: 10639447
   PubMed Web of Science ®Google Scholar
• Li Z, Howard A, Kelley C, Delogu G, Collins F, Morris S. Immunogenicity of DNA vaccines expressing tuberculosis proteins fused to tissue plasminogen activator signal sequences. Infect Immun 1999; 67:4780 - 6; PMID: 10456931
   PubMed Web of Science ®Google Scholar
• Grover A, Ahmed MF, Singh B, Verma I, Sharma P, Khuller GK. A multivalent combination of experimental antituberculosis DNA vaccines based on Ag85B and regions of difference antigens. Microbes Infect 2006; 8:2390 - 9; http://dx.doi.org/10.1016/j.micinf.2006.04.025; PMID: 16962360
   PubMed Web of Science ®Google Scholar
• Derrick SC, Yang AL, Morris SL. A polyvalent DNA vaccine expressing an ESAT6-Ag85B fusion protein protects mice against a primary infection with Mycobacterium tuberculosis and boosts BCG-induced protective immunity. Vaccine 2004; 23:780 - 8; http://dx.doi.org/10.1016/j.vaccine.2004.07.036; PMID: 15542202
   PubMed Web of Science ®Google Scholar
• Bertholet S, Ireton GC, Ordway DJ, Windish HP, Pine SO, Kahn M, Phan T, Orme IM, Vedvick TS, Baldwin SL, et al. A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis. Sci Transl Med 2010; 2:53ra74; http://dx.doi.org/10.1126/scitranslmed.3001094; PMID: 20944089
   PubMed Web of Science ®Google Scholar
• Skjøt RL, Brock I, Arend SM, Munk ME, Theisen M, Ottenhoff TH, Andersen P. Epitope mapping of the immunodominant antigen TB10.4 and the two homologous proteins TB10.3 and TB12.9, which constitute a subfamily of the esat-6 gene family. Infect Immun 2002; 70:5446 - 53; http://dx.doi.org/10.1128/IAI.70.10.5446-5453.2002; PMID: 12228269
   PubMed Web of Science ®Google Scholar
• Elvang T, Christensen JP, Billeskov R, Thi Kim Thanh Hoang T, Holst P, Thomsen AR, Andersen P, Dietrich J. CD4 and CD8 T cell responses to the M. tuberculosis Ag85B-TB10.4 promoted by adjuvanted subunit, adenovector or heterologous prime boost vaccination. PLoS One 2009; 4:e5139; http://dx.doi.org/10.1371/journal.pone.0005139; PMID: 19357780
   PubMed Web of Science ®Google Scholar
• Dietrich J, Aagaard C, Leah R, Olsen AW, Stryhn A, Doherty TM, Andersen P. Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy. J Immunol 2005; 174:6332 - 9; http://dx.doi.org/10.4049/jimmunol.174.10.6332; PMID: 15879133
   PubMed Web of Science ®Google Scholar
• Mahmood A, Srivastava S, Tripathi S, Ansari MA, Owais M, Arora A. Molecular characterization of secretory proteins Rv3619c and Rv3620c from Mycobacterium tuberculosis H37Rv. FEBS J 2011; 278:341 - 53; http://dx.doi.org/10.1111/j.1742-4658.2010.07958.x; PMID: 21134129
   PubMed Web of Science ®Google Scholar
• Yan J, Reichenbach DK, Corbitt N, Hokey DA, Ramanathan MP, McKinney KA, Weiner DB, Sewell D. Induction of antitumor immunity in vivo following delivery of a novel HPV-16 DNA vaccine encoding an E6/E7 fusion antigen. Vaccine 2009; 27:431 - 40; http://dx.doi.org/10.1016/j.vaccine.2008.10.078; PMID: 19022315
   PubMed Web of Science ®Google Scholar
• Shedlock DJ, Aviles J, Talbott KT, Wong G, Wu SJ, Villarreal DO, Myles DJ, Croyle MA, Yan J, Kobinger GP, et al. Induction of broad cytotoxic T cells by protective DNA vaccination against Marburg and Ebola. Mol Ther 2013; 21:1432 - 44; http://dx.doi.org/10.1038/mt.2013.61; PMID: 23670573
   PubMed Web of Science ®Google Scholar
• Cooper AM. Cell-mediated immune responses in tuberculosis. Annu Rev Immunol 2009; 27:393 - 422; http://dx.doi.org/10.1146/annurev.immunol.021908.132703; PMID: 19302046
   PubMed Web of Science ®Google Scholar
• Derrick SC, Repique C, Snoy P, Yang AL, Morris S. Immunization with a DNA vaccine cocktail protects mice lacking CD4 cells against an aerogenic infection with Mycobacterium tuberculosis. Infect Immun 2004; 72:1685 - 92; http://dx.doi.org/10.1128/IAI.72.3.1685-1692.2004; PMID: 14977976
   PubMed Web of Science ®Google Scholar
• Pym AS, Brodin P, Brosch R, Huerre M, Cole ST. Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti. Mol Microbiol 2002; 46:709 - 17; http://dx.doi.org/10.1046/j.1365-2958.2002.03237.x; PMID: 12410828
   PubMed Web of Science ®Google Scholar
• Pym AS, Brodin P, Majlessi L, Brosch R, Demangel C, Williams A, Griffiths KE, Marchal G, Leclerc C, Cole ST. Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nat Med 2003; 9:533 - 9; http://dx.doi.org/10.1038/nm859; PMID: 12692540
   PubMed Web of Science ®Google Scholar
• Murray RA, Mansoor N, Harbacheuski R, Soler J, Davids V, Soares A, Hawkridge A, Hussey GD, Maecker H, Kaplan G, et al. Bacillus Calmette Guerin vaccination of human newborns induces a specific, functional CD8+ T cell response. J Immunol 2006; 177:5647 - 51; http://dx.doi.org/10.4049/jimmunol.177.8.5647; PMID: 17015753
   PubMed Web of Science ®Google Scholar
• Gordon SV, Brosch R, Billault A, Garnier T, Eiglmeier K, Cole ST. Identification of variable regions in the genomes of tubercle bacilli using bacterial artificial chromosome arrays. Mol Microbiol 1999; 32:643 - 55; http://dx.doi.org/10.1046/j.1365-2958.1999.01383.x; PMID: 10320585
   PubMed Web of Science ®Google Scholar
• Kutzler MA, Weiner DB. DNA vaccines: ready for prime time?. Nat Rev Genet 2008; 9:776 - 88; http://dx.doi.org/10.1038/nrg2432; PMID: 18781156
   PubMed Web of Science ®Google Scholar
• Villarreal DO, Talbott KT, Choo DK, Shedlock DJ, Weiner DB. Synthetic DNA vaccine strategies against persistent viral infections. Expert Rev Vaccines 2013; 12:537 - 54; http://dx.doi.org/10.1586/erv.13.33; PMID: 23659301
   PubMed Web of Science ®Google Scholar
• Bagarazzi ML, Yan J, Morrow MP, Shen X, Parker RL, Lee JC, Giffear M, Pankhong P, Khan AS, Broderick KE, et al. Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses. Sci Transl Med 2012; 4:ra138; http://dx.doi.org/10.1126/scitranslmed.3004414; PMID: 23052295
   PubMed Web of Science ®Google Scholar
• Kalams SA, Parker SD, Elizaga M, Metch B, Edupuganti S, Hural J, De Rosa S, Carter DK, Rybczyk K, Frank I, et al, NIAID HIV Vaccine Trials Network. Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid IL-12 and impact of intramuscular electroporation for delivery. J Clin Investigation. J Infect Dis 2013; 208:818 - 29; http://dx.doi.org/10.1093/infdis/jit236; PMID: 23840043
   PubMed Web of Science ®Google Scholar
• Hirao LA, Wu L, Khan AS, Hokey DA, Yan J, Dai A, Betts MR, Draghia-Akli R, Weiner DB. Combined effects of IL-12 and electroporation enhances the potency of DNA vaccination in macaques. Vaccine 2008; 26:3112 - 20; http://dx.doi.org/10.1016/j.vaccine.2008.02.036; PMID: 18430495
   PubMed Web of Science ®Google Scholar
• Tollefsen S, Tjelle T, Schneider J, Harboe M, Wiker H, Hewinson G, Huygen K, Mathiesen I. Improved cellular and humoral immune responses against Mycobacterium tuberculosis antigens after intramuscular DNA immunisation combined with muscle electroporation. Vaccine 2002; 20:3370 - 8; http://dx.doi.org/10.1016/S0264-410X(02)00289-X; PMID: 12213407
   PubMed Web of Science ®Google Scholar
• Zhang X, Divangahi M, Ngai P, Santosuosso M, Millar J, Zganiacz A, Wang J, Bramson J, Xing Z. Intramuscular immunization with a monogenic plasmid DNA tuberculosis vaccine: Enhanced immunogenicity by electroporation and co-expression of GM-CSF transgene. Vaccine 2007; 25:1342 - 52; http://dx.doi.org/10.1016/j.vaccine.2006.09.089; PMID: 17052817
   PubMed Web of Science ®Google Scholar
• Tollefsen S, Vordermeier M, Olsen I, Storset AK, Reitan LJ, Clifford D, Lowrie DB, Wiker HG, Huygen K, Hewinson G, et al. DNA injection in combination with electroporation: a novel method for vaccination of farmed ruminants. Scand J Immunol 2003; 57:229 - 38; http://dx.doi.org/10.1046/j.1365-3083.2003.01218.x; PMID: 12641651
   PubMed Web of Science ®Google Scholar
• Uplekar S, Heym B, Friocourt V, Rougemont J, Cole ST. Comparative genomics of Esx genes from clinical isolates of Mycobacterium tuberculosis provides evidence for gene conversion and epitope variation. Infect Immun 2011; 79:4042 - 9; http://dx.doi.org/10.1128/IAI.05344-11; PMID: 21807910
   PubMed Web of Science ®Google Scholar
• Derrick SC, Yabe IM, Yang A, Morris SL. Vaccine-induced anti-tuberculosis protective immunity in mice correlates with the magnitude and quality of multifunctional CD4 T cells. Vaccine 2011; 29:2902 - 9; http://dx.doi.org/10.1016/j.vaccine.2011.02.010; PMID: 21338678
   PubMed Web of Science ®Google Scholar
• Hervas-Stubbs S, Majlessi L, Simsova M, Morova J, Rojas MJ, Nouzé C, Brodin P, Sebo P, Leclerc C. High frequency of CD4+ T cells specific for the TB10.4 protein correlates with protection against Mycobacterium tuberculosis infection. Infect Immun 2006; 74:3396 - 407; http://dx.doi.org/10.1128/IAI.02086-05; PMID: 16714570
   PubMed Web of Science ®Google Scholar
• Siegrist MS, Unnikrishnan M, McConnell MJ, Borowsky M, Cheng TY, Siddiqi N, Fortune SM, Moody DB, Rubin EJ. Mycobacterial Esx-3 is required for mycobactin-mediated iron acquisition. Proc Natl Acad Sci U S A 2009; 106:18792 - 7; http://dx.doi.org/10.1073/pnas.0900589106; PMID: 19846780
   PubMed Web of Science ®Google Scholar
• Sutcliffe IC. New insights into the distribution of WXG100 protein secretion systems. Antonie Van Leeuwenhoek 2011; 99:127 - 31; http://dx.doi.org/10.1007/s10482-010-9507-4; PMID: 20852931
   PubMed Web of Science ®Google Scholar
• Hoang TT, Nansen A, Roy S, Billeskov R, Aagaard C, Elvang T, Dietrich J, Andersen P. Distinct differences in the expansion and phenotype of TB10.4 specific CD8 and CD4 T cells after infection with Mycobacterium tuberculosis. PLoS One 2009; 4:e5928; http://dx.doi.org/10.1371/journal.pone.0005928; PMID: 19529765
   PubMedGoogle Scholar
• Bukka A, Price CT, Kernodle DS, Graham JE. Mycobacterium tuberculosis RNA expression patterns in sputum bacteria indicate secreted Esx factors contributing to growth are highly expressed in active disease. Front Microbiol 2011; 2:266; PMID: 22291682
   PubMed Web of Science ®Google Scholar
• Bottai D, Di Luca M, Majlessi L, Frigui W, Simeone R, Sayes F, Bitter W, Brennan MJ, Leclerc C, Batoni G, et al. Disruption of the ESX-5 system of Mycobacterium tuberculosis causes loss of PPE protein secretion, reduction of cell wall integrity and strong attenuation. Mol Microbiol 2012; 83:1195 - 209; http://dx.doi.org/10.1111/j.1365-2958.2012.08001.x; PMID: 22340629
   PubMed Web of Science ®Google Scholar
• Lalvani A, Brookes R, Wilkinson RJ, Malin AS, Pathan AA, Andersen P, Dockrell H, Pasvol G, Hill AV. Human cytolytic and interferon γ-secreting CD8+ T lymphocytes specific for Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 1998; 95:270 - 5; http://dx.doi.org/10.1073/pnas.95.1.270; PMID: 9419365
   PubMed Web of Science ®Google Scholar
• Flynn JL, Goldstein MM, Triebold KJ, Koller B, Bloom BR. Major histocompatibility complex class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection. Proc Natl Acad Sci U S A 1992; 89:12013 - 7; http://dx.doi.org/10.1073/pnas.89.24.12013; PMID: 1465432
   PubMed Web of Science ®Google Scholar
• Tascon RE, Stavropoulos E, Lukacs KV, Colston MJ. Protection against Mycobacterium tuberculosis infection by CD8+ T cells requires the production of gamma interferon. Infect Immun 1998; 66:830 - 4; PMID: 9453650
   PubMed Web of Science ®Google Scholar
• Denis O, Tanghe A, Palfliet K, Jurion F, van den Berg TP, Vanonckelen A, Ooms J, Saman E, Ulmer JB, Content J, et al. Vaccination with plasmid DNA encoding mycobacterial antigen 85A stimulates a CD4+ and CD8+ T-cell epitopic repertoire broader than that stimulated by Mycobacterium tuberculosis H37Rv infection. Infect Immun 1998; 66:1527 - 33; PMID: 9529077
   PubMed Web of Science ®Google Scholar
• Hirao LA, Wu L, Khan AS, Hokey DA, Yan J, Dai A, Betts MR, Draghia-Akli R, Weiner DB. Combined effects of IL-12 and electroporation enhances the potency of DNA vaccination in macaques. Vaccine 2008; 26:3112 - 20; http://dx.doi.org/10.1016/j.vaccine.2008.02.036; PMID: 18430495
   PubMed Web of Science ®Google Scholar
• Kalams SA, Parker SD, Elizaga M, Metch B, Edupuganti S, Hural J, De Rosa S, Carter DK, Rybczyk K, Frank I, et al, NIAID HIV Vaccine Trials Network. Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery. J Infect Dis 2013; 208:818 - 29; http://dx.doi.org/10.1093/infdis/jit236; PMID: 23840043
   PubMed Web of Science ®Google Scholar
• Villarreal DO, Wise MC, Walters JN, Reuschel EL, Choi MJ, Obeng-Adjei N, Yan J, Morrow MP, Weiner DB. Alarmin IL-33 acts as an immunoadjuvant to enhance antigen-specific tumor immunity. Cancer Res 2014; 74:1789 - 800; http://dx.doi.org/10.1158/0008-5472.CAN-13-2729; PMID: 24448242
   PubMed Web of Science ®Google Scholar
• Yan J, Corbitt N, Pankhong P, Shin T, Khan A, Sardesai NY, Weiner DB. Immunogenicity of a novel engineered HIV-1 clade C synthetic consensus-based envelope DNA vaccine. Vaccine 2011; 29:7173 - 81; http://dx.doi.org/10.1016/j.vaccine.2011.05.076; PMID: 21651948
   PubMed Web of Science ®Google Scholar
• Laddy DJ, Yan J, Corbitt N, Kobasa D, Kobinger GP, Weiner DB. Immunogenicity of novel consensus-based DNA vaccines against avian influenza. Vaccine 2007; 25:2984 - 9; http://dx.doi.org/10.1016/j.vaccine.2007.01.063; PMID: 17306909
   PubMed Web of Science ®Google Scholar
• Hogarth PJ, Logan KE, Vordermeier HM, Singh M, Hewinson RG, Chambers MA. Protective immunity against Mycobacterium bovis induced by vaccination with Rv3109c--a member of the esat-6 gene family. Vaccine 2005; 23:2557 - 64; http://dx.doi.org/10.1016/j.vaccine.2004.11.030; PMID: 15780437
   PubMed Web of Science ®Google Scholar
• Shedlock DJ, Talbott KT, Wu SJ, Wilson CM, Muthumani K, Boyer JD, Sardesai NY, Awasthi S, Weiner DB. Vaccination with synthetic constructs expressing cytomegalovirus immunogens is highly T cell immunogenic in mice. Hum Vaccin Immunother 2012; 8:1668 - 81; http://dx.doi.org/10.4161/hv.22447; PMID: 23151448
   PubMed Web of Science ®Google Scholar
• Yan J, Yoon H, Kumar S, Ramanathan MP, Corbitt N, Kutzler M, Dai A, Boyer JD, Weiner DB. Enhanced cellular immune responses elicited by an engineered HIV-1 subtype B consensus-based envelope DNA vaccine. Mol Ther 2007; 15:411 - 21; http://dx.doi.org/10.1038/sj.mt.6300036; PMID: 17235321
   PubMed Web of Science ®Google Scholar